CRISPR Therapeutics AG held its Annual General Meeting on June 5, 2025. Shareholders approved the Swiss management report, consolidated financial statements, and statutory financial statements for the year ended December 31, 2024. The appropriation of financial results was also approved. Additionally, the transaction of any other business that properly came before the meeting was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.